IP Library › Granted Patent US 9,175,064
Granted Patent B2
US 9,175,064 · App. 10/578,139 · Granted Nov 3, 2015

HLA-E chimeric molecule

Inventors: Shuji Miyagawa (Ashiya, JP); Katsuyoshi Matsunami (Hiroshima, JP)
C07K14/70539A01K2267/02C07K2319/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,175,064
App. No.
10/578,139
Granted
Nov 3, 2015
Kind
B2
Abstract

HLA-E chimeric molecules for providing nonhuman mammalian cells resistant to cytotoxic human NK cells, nucleotide sequences encoding these chimeric molecules, and nonhuman mammalian cells and nonhuman mammals transformed with such nucleotide sequences are disclosed herein. The HLA-E chimeric molecules of the invention contain a peptide that reforms all or part of the signal peptide region, α1 domain and/or α2 domain of HLA-E, and a nucleotide sequence of the invention encodes a HLA-E chimeric molecule. A transformant incorporating a nucleotide sequence of the invention expresses HLA-E efficiently.

Claims (4)

1. An HLA-E chimeric molecule that when expressed in a nonhuman mammal cell, is expressed at the cell surface and that possesses one of the following amino acid sequences:

(1) an HLA-E chimeric molecule wherein the signal peptide (SP) of an HLA-E molecule has been replaced with a reformed SP, wherein the sequence of the reformed SP is SEQ ID NO:21, and the serine corresponding to amino acid 57 of SEQ ID NO: 3 of the α2 domain of the HLA-E molecule has been replaced with cysteine,

(2) an HLA-E chimeric molecule wherein the signal peptide (SP) of an HLA-E molecule has been replaced with a reformed SP, wherein the sequence of the reformed SP is SEQ ID NO:21, the serine corresponding to amino acid 11 of SEQ ID NO:2 of the α1 domain of the HLA-E molecule has been replaced with alanine; and the serine corresponding to amino acid 57 of SEQ ID NO: 3 of the α2 domain of the HLA-E molecule has been replaced with cysteine, and

(3) an HLA-E chimeric molecule wherein the signal peptide (SP) of an HLA-E molecule has been replaced with a reformed SP, wherein the sequence of the reformed SP is SEQ ID NO: 21, and the first portion of the latter part of the α2 domain of the HLA-E chimeric molecule, corresponding to amino acids 47-60 of SEQ ID NO: 3 has been replaced with the first portion of the latter part of the α2 domain of the HLA-G1 molecule, corresponding to amino acids 47-60 of SEQ ID NO: 13, wherein the amino acid sequences of the signal peptide (SP), α1 domain, α2 domain, α3 domain and transmembrane domain of the HLA-E molecule are SEQ ID NO: 1-5, respectively.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 6, 2016
From: THE ANIMAL ENGINEERING RESEARCH INSTITUTE CO., LTD.
To: NH FOODS LTD.; NIPRO CORPORATION
Reel/Frame 039078/0081 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 17, 2006
From: MIYAGAWA, SHUJI; MATSUNAMI, KATSUYOSHI
To: ANIMAL ENGINERING RESEARCH INSTITUTE, THE
Reel/Frame 017950/0202 →
Priority Claims (1)
JP 2003-374944 · Nov 4, 2003 · national
Continuity (1)
Related Publication 20070259403A1 · Nov 8, 2007